On May 19, 2014, VIVUS, Inc. (NASDAQ:VVUS)’s shares declined 0.43% to $4.68. The company announced that a poster describing results of a clinical study examining onset of action of avanafil will be presented during the American Urological Association Annual Meeting in Orlando, FL. VIVUS, Inc. (NASDAQ:VVUS), weekly performance is -7.27%. On last trading day company shares ended up $4.59. Analysts mean target price for the company is $7.33. VIVUS, Inc. (NASDAQ:VVUS), distance from 50-day simple moving average (SMA50) is -14.58%.
On May 12, 2014, Verastem Inc (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the appointment of Paul A. Friedman, M.D. to its Board of Directors. Verastem Inc (NASDAQ:VSTM), advanced 10.16% in last trading session and ended the day on $9.00. VSTM, return on assets is -38.90%. Verastem Inc (NASDAQ:VSTM), quarterly performance is -40.08%.
QLT Inc. (USA) (NASDAQ:QLTI), saw a big move last session, as the company’s shares fell by over 9% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the most recent downtrend for QLTI as the stock is now down nearly 22% since April 24. QLT Inc. (USA) (NASDAQ:QLTI), shares moved up 8.33% in last trading session and was closed at $5.33, while trading in range of $4.90 – 5.53. QLT Inc. (USA) (NASDAQ:QLTI), year to date (YTD) performance is -29.38%.
On May 15, 2014, Reckitt Benckiser Group’s pharmaceuticalsunit will develop and sell XenoPort, Inc. (NASDAQ:XNPT), drug to treat alcoholism, the companies said. XenoPort, Inc. (NASDAQ:XNPT), ended the last trading day at $3.72. Company weekly volatility is calculated as 6.58% and price to cash ratio as 1.88. XenoPort, Inc. (NASDAQ:XNPT), showed a positive weekly performance of 1.64%.
Amicus Therapeutics, Inc. (NASDAQ:FOLD), had its price objective cut by Leerink Swann from $3.00 to $2.50 in a report released on Tuesday, Stock Ratings News reports. Amicus Therapeutics, Inc. (NASDAQ:FOLD), weekly performance is 0.46%. On last trading day company shares ended up $2.20. Analysts mean target price for the company is $3.67. Amicus Therapeutics, Inc. (NASDAQ:FOLD), distance from 50-day simple moving average (SMA50) is 4.68%.